
Vitroscope raises $5 million seed plus $2 million research funding for live-tissue experiments
Individually labelled portraits from Vitroscope’s official website.Left to right: Heikki Sjöman (CTO and co-founder); Sandra Jernström (CBDO and co-founder); Carlo Kriesi (CEO and co-founder).Vitroscope has raised $7 million, comprising a $5 million seed round co-led by Cerberus Ventures and YZR Capital and $2 million in non-dilutive funding from the Research Council of Norway. The Trondheim company builds perfusion platforms: laboratory systems that circulate fluid through living tissue while controlling conditions such as oxygen, pH and temperature. Its vitro.alive benchtop system combines those controls with live-cell imaging for six independent experiments in parallel, using standard inverted microscopes and researchers' existing tissue models. The money will support commercial rollout of vitro.alive and validation of the higher-throughput vitro.scale platform. Vitro.scale remains in development, with customer testing expected in 2027 and a planned 2028 launch. Cumulative funding is $8.8 million, including the new package.
DTT summary based on Vitroscope / Business Wire's report. The full article is on the publisher's site.
Additional reporting
$5 million seed equity plus $2 million non-dilutive research funding.
Cerberus Ventures and YZR Capital.
Arcas Ventures, Golden Egg Check, Devico Invest; angels Carles Reina, Fàtima Godall and Oskari Pétas.
$2 million from the Research Council of Norway.
Controlled fluid flow through living tissue with oxygen, pH and temperature control and live-cell imaging.
vitro.alive supports six independent experiments with standard inverted microscopes.
vitro.scale: 96 parallel experiments in development; customer testing expected 2027, planned launch 2028.
$8.8 million total funding to date, company-reported. Valuation not disclosed.